ReceptivaDX

Predict Chances For A Successful Transfer And Pregnancy

ReceptivaDX is a groundbreaking test that detects a protein called BCL6, which is linked to inflammation in the uterus. High levels of this protein are often associated with endometriosis and can make it harder for an embryo to attach to the uterine lining, potentially affecting fertility.

Patients testing positive for BCL6 are 5 times less likely to succeed with in vitro fertilization (IVF) than patients testing negative. If a patient tests positive and endometriosis is suspected, it can then be treated by a physician to increase the chances of pregnancy success. A negative BCL6 result provides reassurance to patients that endometriosis is not of concern.

How the ReceptivaDX Test Works

The ReceptivaDx Test is conducted using a sample from an endometrial biopsy, a routine procedure that can typically be performed during a regular office visit with a reproductive specialist. If the test result is positive, there are two treatment options for IVF patients: hormone therapy to reduce inflammation or laparoscopic surgery to remove the problematic tissue. Removing endometriosis around the endometrial lining has also been proven to increase the chances of conception even without IVF.